AFX & Pleomorphic Dermal Sarcoma: Mohs Indications & Treatment

Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are UV-induced cutaneous sarcomas that are now recognized as representing a single biologic spectrum rather than distinct entities. The WHO Classification of Skin Tumours (5th edition, 2023) classifies both under the category of undifferentiated/unclassified sarcomas of the skin. AFX represents the superficial, dermis-confined, favorable end of the spectrum, while PDS represents the deeper, more aggressive end with extension into the subcutaneous fat and/or the presence of adverse histologic features. The nomenclature has evolved significantly: historically AFX was considered a benign or low-grade tumor with universally excellent prognosis, but the recognition that tumors with identical cytomorphology but deeper invasion or adverse features carry significant metastatic potential led to the distinction of PDS as a separate prognostic category. The estimated incidence of AFX/PDS combined is approximately 0.3-0.5 per 100,000 per year, though this is likely underestimated due to historical misdiagnosis and inconsistent nomenclature. Both AFX and PDS arise predominantly on chronically sun-damaged skin of the head and neck in elderly men. The typical patient is a male over 70 years old with extensive actinic damage. The scalp, ears, nose, and cheeks are the most common sites, with over 80% of cases occurring on the head and neck. Unlike DFSP, which affects younger adults on the trunk, the AFX-PDS spectrum is strongly associated with cumulative UV exposure and occurs almost exclusively in the elderly. Immunosuppression, prior radiation therapy, and xeroderma pigmentosum are additional risk factors.

AFX and PDS typically present as a rapidly growing, dome-shaped, pink to red nodule on sun-damaged skin of the head and neck. The lesion often develops over weeks to a few months, distinguishing it from the more indolent growth pattern of BCC. Ulceration is common and may be the presenting complaint, as the rapidly growing tumor outstrips its blood supply. The size at presentation is typically 1-2 cm for AFX, though PDS may present at larger sizes. The surface may be smooth, exophytic, polypoid, or crusted with ulceration. Bleeding is a common symptom, often prompting clinical attention. The clinical appearance is nonspecific and closely mimics other common tumors on sun-damaged skin. The clinical differential diagnosis includes squamous cell carcinoma (the most common clinical misdiagnosis), basal cell carcinoma (nodular type), keratoacanthoma, amelanotic melanoma, Merkel cell carcinoma, and cutaneous metastasis. There are no pathognomonic clinical features that distinguish AFX/PDS from these entities, making biopsy mandatory for any rapidly growing nodule on actinically damaged skin of elderly patients. On examination, the surrounding skin typically shows extensive photodamage with solar elastosis, actinic keratoses, and often a history of prior skin cancers. This field cancerization context is important diagnostically. Regional lymphadenopathy is uncommon at presentation for AFX but should be assessed for PDS, particularly in tumors with high-risk features.

AFX and PDS share identical cytomorphologic features. Both are characterized by a dermal proliferation of highly pleomorphic spindle cells, epithelioid cells, and bizarre multinucleated giant cells arranged in a haphazard or storiform pattern. The mitotic rate is typically high (>10 mitoses per 10 HPF), and atypical mitotic figures are frequent. The degree of nuclear pleomorphism is striking, often more dramatic than in the tumors being excluded (SCC, melanoma, leiomyosarcoma), and paradoxically this extreme pleomorphism can be a diagnostic clue favoring AFX/PDS. The overlying epidermis frequently shows epidermal collarette formation at the periphery of the tumor, and the adjacent dermis shows pronounced solar elastosis. The tumor stroma may contain inflammatory infiltrates and areas of hemorrhage. The most critical diagnostic principle for AFX/PDS is that it is a diagnosis of EXCLUSION. There is no single positive immunohistochemical marker that confirms the diagnosis. Instead, the diagnosis requires systematic exclusion of all specific lineage-differentiated tumors that can mimic this histologic pattern. The hallmark IHC finding is negativity for all lineage-specific markers.

The distinction between AFX and PDS is the most clinically consequential classification decision in this tumor spectrum, as it determines prognosis, follow-up intensity, and the need for adjuvant therapy. AFX, by definition confined to the dermis and lacking adverse histologic features, behaves as a low-grade tumor with an excellent prognosis. The local recurrence rate after complete excision is approximately 5-10%, and the metastatic rate is less than 1%. In contrast, PDS is a significantly more aggressive tumor with a local recurrence rate of 10-20% after standard excision, a metastatic rate of 10-20%, and disease-specific mortality reported at 5-10% in published series. The most common sites of distant metastasis for PDS are the lungs and regional lymph nodes, though metastases to bone, brain, and other visceral sites have been reported. The dramatic difference in biologic behavior between AFX and PDS underscores the importance of accurate histopathologic classification and the danger of lumping both entities together under the AFX label.

Mohs micrographic surgery (MMS) is the treatment of choice for both AFX and PDS. The rationale for Mohs in AFX/PDS is particularly compelling: these tumors arise on chronically sun-damaged skin of the head and neck. The same field cancerization environment that produces BCCs and SCCs. Making subclinical extension along sun-damaged tissue planes a genuine concern. Mohs provides complete peripheral and deep margin assessment (100% margin evaluation) in a setting where clinical margin estimation is unreliable due to the field cancerization and actinic damage of surrounding skin. Published local recurrence rates after Mohs for AFX are approximately 0-2%, compared to 5-10% after standard excision. For PDS, Mohs achieves local recurrence rates of approximately 2-8%, compared to 10-20% after wide local excision. These superior recurrence rates reflect the advantage of complete margin assessment in a tumor that can have irregular subclinical extension. Additionally, Mohs offers critical tissue conservation on the head and neck, where the majority of AFX/PDS tumors occur. The scalp, nose, ears, and periauricular areas are common sites where standard excision with 1-2 cm margins may produce large defects requiring complex reconstruction.

The treatment algorithm for AFX/PDS depends critically on the distinction between the two entities and the presence or absence of adverse histologic features. For AFX (dermis-confined, no adverse features), Mohs micrographic surgery alone is curative in the vast majority of cases. No adjuvant therapy is required, and standard post-treatment surveillance is sufficient. For PDS, the management approach is more individualized and should incorporate multidisciplinary discussion.

The prognosis of AFX is excellent with appropriate surgical management. Local recurrence rates after Mohs are 0-2%, and metastasis occurs in fewer than 1% of cases. Disease-specific mortality from true, dermis-confined AFX is negligible. Patients with AFX can be reassured about the favorable prognosis while being counseled about the importance of ongoing skin cancer surveillance, given that the same UV-damaged skin is at risk for developing additional primary skin cancers (BCC, SCC, new AFX/PDS, or melanoma). The prognosis of PDS is significantly less favorable. Local recurrence rates after excision range from 10-20% (lower with Mohs, approximately 2-8%). Metastasis occurs in 10-20% of PDS cases, with the lungs and regional lymph nodes being the most common metastatic sites. Disease-specific mortality for PDS is reported at 5-10% in published series. Adverse prognostic factors within PDS include tumor necrosis, lymphovascular invasion, perineural invasion, tumor size >2 cm, depth of invasion beyond the subcutis (into fascia or muscle), and positive surgical margins. Recurrence of PDS, both local and distant, typically occurs within the first 2 years after treatment, though late recurrences have been reported.